Patents by Inventor Gaëtan LIGAT

Gaëtan LIGAT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies and peptides to treat HCMV related diseases
    Patent number: 11174322
    Abstract: The present invention relates to the treatment of HCMV relates diseases. The inventors conducted a study to find an essential domain of pUL56 for its interaction with pUL89 which is important in the effect of the CMV. Sequences alignments allowed them to predict one sequence in C-terminal of pUL56 potentially necessary for interaction with pUL89. BAC mutagenesis and AlphaLISA technologies using purified proteins allowed to validate that the short sequence 671WMVVKYMGFF680 (SEQ ID NO: 1) in C-terminal of pUL56 is involved in interaction with pUL89. Knowing this important information, antibodies directed against this sequence or peptides derived from this sequence could be useful to invalidate the interaction of pUL56 to pUL89 and thus to treat HCMV related diseases.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 16, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER Régional Universitaire de Limoges, Universitéde Limoges
    Inventors: Sophie Alain, Gaëtan Ligat, Sébastien Hantz, Anthony Couvreux
  • ANTIBODIES AND PEPTIDES TO TREAT HCMV RELATED DISEASES
    Publication number: 20200207873
    Abstract: The present invention relates to the treatment of HCMV relates diseases. The inventors conducted a study to find an essential domain of pUL56 for its interaction with pUL89 which is important in the effect of the CMV. Sequences alignments allowed them to predict one sequence in C-terminal of pUL56 potentially necessary for interaction with pUL89. BAC mutagenesis and AlphaLISA technologies using purified proteins allowed to validate that the short sequence 671WMVVKYMGFF680 (SEQ ID NO: 1) in C-terminal of pUL56 is involved in interaction with pUL89. Knowing this important information, antibodies directed against this sequence or peptides derived from this sequence could be useful to invalidate the interaction of pUL56 to pUL89 and thus to treat HCMV related diseases.
    Type: Application
    Filed: July 19, 2018
    Publication date: July 2, 2020
    Inventors: Sophie ALAIN, Gaëtan LIGAT, Sébastien HANTZ, Anthony COUVREUX